Ipsen’s Q2 sales came in ahead of expectations. Neuroscience continued its strong momentum and even ‘patented’ Oncology managed to offset the decline for an off-patent drug. More importantly, the 2023 guidance was also upgraded. Overall, considering the healthy momentum for the existing drugs along with a slew of readouts in the near term and the balance sheet flex to pursue an external innovation strategy, our positive recommendation is maintained.
